Before I even started pharmacy school, I knew I wanted to own an independent pharmacy. That dream always included compounding. I saw it as essential, not just for building a business, but for offering patients something more meaningful. Something more personal.

As compounding pharmacists, we’re often on the front lines when patients and providers start exploring emerging therapies — especially those that live in the grey space between hopeful promise and clinical validation. The recent PCCA webinar on Mebendazole and Ivermectin in Oncology addressed just that. If you missed it, here are the key takeaways, insights and cautionary notes from the session — tailored for your role behind the counter and in the consult room.

I’m Max Lugavere — a health and science journalist, New York Times bestselling author, filmmaker and host of The Genius Life podcast. I’ve spent more than a decade obsessed with answering one core question: how can we live better, longer — and feel amazing doing it?

At PCCA, we strive to lead through innovation and are defined by our unwavering commitment to quality. That’s why we’re proud to share some exciting news: LoxOral® and Anhydrous SuspendIt®, two of our most widely used proprietary bases, are now part of the U.S. Pharmacopeia (USP) Ingredient Verification Program for Excipients.